Forums » News and Announcements

Evaluation of degarelix in the management of prostate cancer

    • 1370 posts
    October 7, 2019 8:00 AM EDT
    Medical castration using gonadotropin-releasing hormone (GnRH) receptor
    agonists currently provides the mainstay of androgen deprivation therapy
    for prostate cancer. Although effective, these agents only reduce
    testosterone levels after a delay of 14 to 21 days; they also cause an
    initial surge in testosterone that can stimulate the cancer and lead to
    exacerbation of symptoms ("clinical flare") in patients with advanced
    disease. Phase III trial data for the recently approved GnRH receptor
    blocker, degarelix, demonstrated that it is as effective and well
    tolerated as GnRH agonists.Degarelix powder

    However, it has a pharmacological profile more closely matching
    orchiectomy, with an immediate onset of action and faster testosterone
    and PSA suppression, without a testosterone surge or microsurges
    following repeated injections. As a consequence, with this GnRH blocker,
    there is no risk of clinical flare and no need for concomitant
    antiandrogen flare protection. Degarelix therefore provides a useful
    addition to the hormonal armamentarium for prostate cancer and offers a
    valuable new treatment option for patients with hormone-sensitive
    advanced disease. Here, we review key preclinical and clinical data for
    degarelix, and look at patient-focused perspectives in the management of
    prostate cancer.